Burning Rock Biotech Ltd. (BNR) - שולי רווח גולמי

Burning Rock Biotech (BNR) is overcoming the market downturn in China by optimizing expenses amid pricing wars. The gross margin clearly demonstrates the long-term development vector, with the latest value recorded as 74.50. This NGS diagnostics leader is investing in AI-driven blood analysis. Simultaneously, Burning Rock Biotech (BNR) is implementing eco-friendly bio-waste disposal standards, reducing laboratory energy consumption to protect the environment.
פילוחים אנליטיים ודוחות נתונים של חברת Burning Rock (BNR)

Burning Rock Biotech operates under severe pricing pressure and dependence on Chinese oncology diagnostics regulations. The current value of 74.50 reflects the revenue share minus direct production costs, allowing for an assessment of cost management efficiency amid a shortage of Western reagents, while the gross margin trend visualizes the business model's resilience to external risks.